Inmed Pharmaceuticals Inc (INM)

$0.89 +0.01 (1.27%)
Market Cap 2.57M
Revenue (ttm) 4.94M
Net Income (ttm) -8.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -165.18%
Debt to Equity Ratio 0.00
Volume 40,600
Avg Vol 93,560
Day's Range N/A - N/A
Shares Out 2.92M
Stochastic %K 35%
Beta 0.41
Analysts Strong Buy
Price Target $45.00

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 604 669 7207
Fax: 778 945 6800
Address:
885 West Georgia Street, Suite 1445, Vancouver, Canada
BillionerOfKing
BillionerOfKing Feb. 26 at 3:53 AM
$INM Current Stock Price: $0.89
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 11:42 PM
$INM RSI: 34.06, MACD: -0.0716 Vol: 0.09, MA20: 0.95, MA50: 1.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PenkeInvesting
PenkeInvesting Feb. 25 at 9:54 PM
Fundamental analysis of $INM (InMed Pharmaceuticals Inc.) based on financial data and reported results. #INM #InMed
0 · Reply
TakesMoneyToLoseMoney
TakesMoneyToLoseMoney Feb. 23 at 5:40 AM
$INM CEO used to say E.coli biosynthesis of cannabinoids was superior to yeast. then couldnt state if cannabinoids are water soluble. a supposed trained chemist. just know, he sold all his shares 2018 at peak price, crashing sp. this is a cannaScam
0 · Reply
investingisswag
investingisswag Feb. 22 at 2:53 PM
$INM
0 · Reply
HelenPinegar1045
HelenPinegar1045 Feb. 21 at 8:19 AM
$INM InMed Pharmaceuticals develops cannabinoid therapies. Clinical milestones drive valuation. Early-stage risk remains high.
0 · Reply
Offtheschneid
Offtheschneid Feb. 13 at 3:01 PM
$INM I own five shares at an average of $1,674/share. Run away from this company. They will reverse split to keep it over $1. Looking forward to owning 2 shares at $3000+. 🫣😥
0 · Reply
ScoobyDoo_Esquire
ScoobyDoo_Esquire Feb. 12 at 7:49 PM
$INM Very risky being here as this could absolutely get delisted — small starter in hopes they go for warrants. Anything’s on the table when Sabby’s the Captai .
0 · Reply
Space0
Space0 Feb. 12 at 4:02 PM
With $INM now trading under $1 and issuing a going concern warning, are we facing possible delisting and heavy dilution? What protections, if any, are in place for current shareholders ?
0 · Reply
peel1824
peel1824 Feb. 12 at 12:49 PM
$INM 3 reverse splits jul 20. 1/33 share Sept 21. 1/25 share Nov 14 1/20 share Clowns ! 🤡
0 · Reply
Latest News on INM
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 11, 2026, 5:23 PM EST - 14 days ago

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

Dec 17, 2025, 8:59 PM EST - 2 months ago

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

InMed Announces Results of 2025 Annual General and Special Meeting

Dec 17, 2025, 8:00 PM EST - 2 months ago

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Provides Update on BayMedica Commercial Business

Dec 12, 2025, 5:31 PM EST - 2 months ago

InMed Provides Update on BayMedica Commercial Business

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 18, 2025, 7:30 AM EST - 3 months ago

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:51 PM EST - 3 months ago

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 4 months ago

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 4 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

ZYME

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 23, 2025, 8:30 AM EDT - 5 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 16, 2025, 1:39 PM EDT - 5 months ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 1:33 PM EDT - 6 months ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jul 28, 2025, 7:00 AM EDT - 7 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 27, 2025, 7:00 AM EDT - 8 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 8 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 24, 2025, 7:00 AM EDT - 8 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Jun 13, 2025, 4:30 PM EDT - 9 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025, 6:00 PM EDT - 10 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 1 year ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Feb 3, 2025, 7:30 AM EST - 1 year ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 22, 2025, 7:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Jan 21, 2025, 7:30 AM EST - 1 year ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 1 year ago

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 1 year ago

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 19, 2024, 7:30 AM EST - 1 year ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 4:45 PM EST - 1 year ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 8, 2024, 4:44 PM EST - 1 year ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Nov 5, 2024, 8:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024, 8:30 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 16, 2024, 8:00 AM EDT - 2 years ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Apr 4, 2024, 8:00 AM EDT - 2 years ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Mar 20, 2024, 8:30 AM EDT - 2 years ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 13, 2024, 5:41 PM EST - 2 years ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Feb 9, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 18, 2024, 4:41 PM EST - 2 years ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Jan 16, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 2 years ago

InMed Announces Results of 2023 Annual General Meeting

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 14, 2023, 8:04 AM EST - 2 years ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 7:15 PM EDT - 2 years ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

BillionerOfKing
BillionerOfKing Feb. 26 at 3:53 AM
$INM Current Stock Price: $0.89
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 11:42 PM
$INM RSI: 34.06, MACD: -0.0716 Vol: 0.09, MA20: 0.95, MA50: 1.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PenkeInvesting
PenkeInvesting Feb. 25 at 9:54 PM
Fundamental analysis of $INM (InMed Pharmaceuticals Inc.) based on financial data and reported results. #INM #InMed
0 · Reply
TakesMoneyToLoseMoney
TakesMoneyToLoseMoney Feb. 23 at 5:40 AM
$INM CEO used to say E.coli biosynthesis of cannabinoids was superior to yeast. then couldnt state if cannabinoids are water soluble. a supposed trained chemist. just know, he sold all his shares 2018 at peak price, crashing sp. this is a cannaScam
0 · Reply
investingisswag
investingisswag Feb. 22 at 2:53 PM
$INM
0 · Reply
HelenPinegar1045
HelenPinegar1045 Feb. 21 at 8:19 AM
$INM InMed Pharmaceuticals develops cannabinoid therapies. Clinical milestones drive valuation. Early-stage risk remains high.
0 · Reply
Offtheschneid
Offtheschneid Feb. 13 at 3:01 PM
$INM I own five shares at an average of $1,674/share. Run away from this company. They will reverse split to keep it over $1. Looking forward to owning 2 shares at $3000+. 🫣😥
0 · Reply
ScoobyDoo_Esquire
ScoobyDoo_Esquire Feb. 12 at 7:49 PM
$INM Very risky being here as this could absolutely get delisted — small starter in hopes they go for warrants. Anything’s on the table when Sabby’s the Captai .
0 · Reply
Space0
Space0 Feb. 12 at 4:02 PM
With $INM now trading under $1 and issuing a going concern warning, are we facing possible delisting and heavy dilution? What protections, if any, are in place for current shareholders ?
0 · Reply
peel1824
peel1824 Feb. 12 at 12:49 PM
$INM 3 reverse splits jul 20. 1/33 share Sept 21. 1/25 share Nov 14 1/20 share Clowns ! 🤡
0 · Reply
peel1824
peel1824 Feb. 12 at 12:46 PM
$INM how many times these clowns reverse split ! The management does nothing but get paid … Incompetent asses
0 · Reply
AlwaysLearning72
AlwaysLearning72 Feb. 11 at 10:39 PM
$INM wow, what an incredible opportunity to buy some cheap shares on that dip. 🙂
1 · Reply
MrTicker
MrTicker Feb. 11 at 10:27 PM
$INM https://www.newsfilecorp.com/release/283590
0 · Reply
MrTicker
MrTicker Feb. 11 at 10:27 PM
$INM on the move
0 · Reply
newsfile_corp
newsfile_corp Feb. 11 at 10:24 PM
https://nfne.ws/283590 $INM @inmedpharma #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Ear
0 · Reply
Space0
Space0 Feb. 10 at 7:26 PM
$INM looks good
0 · Reply
WickRaider
WickRaider Feb. 9 at 12:31 PM
$INM is a biotech (InMed Pharmaceuticals) focused on cannabinoids and rare diseases; operating at the intersection of two challenging sectors (cannabis and rare diseases) increases the risk profile.
0 · Reply
Holdlong78
Holdlong78 Feb. 3 at 7:10 PM
$INM but there is a big news coming
0 · Reply
Holdlong78
Holdlong78 Feb. 3 at 7:10 PM
$INM they f***k the price ?????
0 · Reply
TakesMoneyToLoseMoney
TakesMoneyToLoseMoney Feb. 2 at 5:58 PM
$INM send this garbage back yo tsx. what ever happened to nano gels, e coli synthesis, eb cream? does ceo know of cannabinoids are water soluble yet? remember - 2018 stock hot all time high - ceo sold all his shares, crashing price snd its never recovered. its a bio-scam - go back to tsx
0 · Reply
Renato17
Renato17 Feb. 1 at 8:33 PM
https://fintel.io/s/us/inm $INM https://fintel.io/s/us/zldaf look overseas, Glk is and will swoop, biogen will, others S #3 is huge. Not Just About Retail. The rest, top off the wave, strength is below the surface, those were random, domiciled in Canda and Australia, the Canadian traded in the USA. The Aus in Canadia, logic right. NOT RECOMMENDATIONS Knowledge of how konkywonkered the industry is reg wise hence illiquid then burst.
0 · Reply